Is it Time to Dump Kazia Therapeutics Ltd (KZIA) Stock After it Is Higher By 42.15% in a Week?

Thursday, August 13, 2020 1:45 PM | InvestorsObserver Analysts

Overall market sentiment has been neutral on Kazia Therapeutics Ltd (KZIA) stock lately. KZIA receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,neutral
Kazia Therapeutics Ltd has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on KZIA!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With KZIA Stock Today?

Kazia Therapeutics Ltd (KZIA) stock is trading at $6.07 as of 1:39 PM on Thursday, Aug 13, an increase of $0.34, or 5.93% from the previous closing price of $5.73. The stock has traded between $5.64 and $6.10 so far today. Volume today is less active than usual. So far 143,826 shares have traded compared to average volume of 854,676 shares.

To screen for more stocks like Kazia Therapeutics Ltd click here.

More About Kazia Therapeutics Ltd

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Close Update: Stocks Rally Friday Led by Technology to End Week Mixed

Wild Week Ends Up K Shaped

Sector Update: Biotech Stocks Lifting Health Care Sector to Big Advance

Stocks Shrug Off Early Weakness, Poised to Close Sharply Higher

Sector Update: Health Care

Is it Time to Dump Columbia Care Inc (CCHWF) Stock After it Is Down 4.62% in a Week?

Related Companies